Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spero Therapeutics (SPRO) Other financing activities (2017 - 2021)

Historic Other financing activities for Spero Therapeutics (SPRO) over the last 5 years, with Q4 2021 value amounting to $49.3 million.

  • Spero Therapeutics' Other financing activities rose 1312761.39% to $49.3 million in Q4 2021 from the same period last year, while for Dec 2022 it was $49.6 million, marking a year-over-year decrease of 29.35%. This contributed to the annual value of $49.8 million for FY2021, which is 512035.68% up from last year.
  • Spero Therapeutics' Other financing activities amounted to $49.3 million in Q4 2021, which was up 1312761.39% from $265000.0 recorded in Q3 2021.
  • In the past 5 years, Spero Therapeutics' Other financing activities registered a high of $49.3 million during Q4 2021, and its lowest value of $16000.0 during Q1 2019.
  • Moreover, its 5-year median value for Other financing activities was $207500.0 (2020), whereas its average is $3.9 million.
  • Within the past 5 years, the most significant YoY rise in Spero Therapeutics' Other financing activities was 1312761.39% (2021), while the steepest drop was 8948.86% (2021).
  • Over the past 5 years, Spero Therapeutics' Other financing activities (Quarter) stood at $3.1 million in 2017, then plummeted by 75.58% to $749000.0 in 2018, then tumbled by 89.45% to $79000.0 in 2019, then skyrocketed by 372.15% to $373000.0 in 2020, then soared by 13127.61% to $49.3 million in 2021.
  • Its last three reported values are $49.3 million in Q4 2021, $265000.0 for Q3 2021, and $109000.0 during Q2 2021.